Abstracts from the 8th Drug Hypersensitivity Meeting (DHM) (original) (raw)

Abstract

Lessons from drug induced anaphylaxis O01 Evidence of an IgG-induced neutrophil activation pathway during human drug-induced anaphylaxis

Figures (25)

analysis confirmed this association between sST2 and AGEP. A high level of all 4 cytokines, mainly associated with EN with > 10% detached surface, was associated of a higher risk of complications. The dosage of IL15 will be performed to better discriminate DRESS and EN. The prognosis role of cytokine levels at diagnosis should be evaluated with other prognostic factors such as SCORTEN.

analysis confirmed this association between sST2 and AGEP. A high level of all 4 cytokines, mainly associated with EN with > 10% detached surface, was associated of a higher risk of complications. The dosage of IL15 will be performed to better discriminate DRESS and EN. The prognosis role of cytokine levels at diagnosis should be evaluated with other prognostic factors such as SCORTEN.

Conclusion In summary, we provide qualitative profiles for the various medica- tions that can potentially cause SJS/TEN in Asian populations, in addition to comparing those profiles with the corresponding pro- files indicated by a European cohort study and US FDA labeling. The study results indicate a number of significant potential threats that are worthy of further investigation. The provided profiles could help to improve patient safety and increase awareness of clinicians of current medication risk related to SJS/TEN.

Conclusion In summary, we provide qualitative profiles for the various medica- tions that can potentially cause SJS/TEN in Asian populations, in addition to comparing those profiles with the corresponding pro- files indicated by a European cohort study and US FDA labeling. The study results indicate a number of significant potential threats that are worthy of further investigation. The provided profiles could help to improve patient safety and increase awareness of clinicians of current medication risk related to SJS/TEN.

Table 1 (continued) Background Results

Table 1 (continued) Background Results

A-B: localized non-bullous fixed drug eruption; C-D: generalized bullous fixed drug eruption Fig. 1 Results

A-B: localized non-bullous fixed drug eruption; C-D: generalized bullous fixed drug eruption Fig. 1 Results

MLS: macrolides lincosamides streptogramins; PT: patch-tests; FDE: fixed drug eruption; AGEP: acute generalized exanthematous pustulosis; DRESS: drug reaction with eosinophilia and systemic symptoms; SIs/Tl EN: Stevens- Johnson/Toxic Epidermal Necrolysis; a=rovamycin b=spiramycin Table 1 Type of reactions and possibility of patch-tests

MLS: macrolides lincosamides streptogramins; PT: patch-tests; FDE: fixed drug eruption; AGEP: acute generalized exanthematous pustulosis; DRESS: drug reaction with eosinophilia and systemic symptoms; SIs/Tl EN: Stevens- Johnson/Toxic Epidermal Necrolysis; a=rovamycin b=spiramycin Table 1 Type of reactions and possibility of patch-tests

Table 1 Contingency table. Drug causality results in EN patients p-value = 0.001 (Fisher's exact test) LTT sensitivity = 82.4%; Specificity = 71.9%; PPV = 60.9%; NPV = 88.5% k=.501: 95% Cl: 0.194-0.679 4 Data from 23 EN cases

Table 1 Contingency table. Drug causality results in EN patients p-value = 0.001 (Fisher's exact test) LTT sensitivity = 82.4%; Specificity = 71.9%; PPV = 60.9%; NPV = 88.5% k=.501: 95% Cl: 0.194-0.679 4 Data from 23 EN cases

Results Table 1 (continued) Background Conclusion

Results Table 1 (continued) Background Conclusion

CBZ: carbamazepine, nonapeptide: FLFDGSPTY, HLA: HLA-B*1502 mutated frorr PDB code 1XR9

CBZ: carbamazepine, nonapeptide: FLFDGSPTY, HLA: HLA-B*1502 mutated frorr PDB code 1XR9

Correspondence: Annick Barbaud - annick.barbaud@aphp.fr Clinical and Translational Allergy 2018, 8(Suppl 3):P23

Correspondence: Annick Barbaud - annick.barbaud@aphp.fr Clinical and Translational Allergy 2018, 8(Suppl 3):P23

Fig. 1 Case report ee We report a case of DRESS by the consecutive use of three drugs in which the diagnosis was difficult to establish because any drug intake could induce this severe reaction. The allergy work-out should include all involved drugs. LTT has been useful to identify the etiological agent (Fig. 1).

Fig. 1 Case report ee We report a case of DRESS by the consecutive use of three drugs in which the diagnosis was difficult to establish because any drug intake could induce this severe reaction. The allergy work-out should include all involved drugs. LTT has been useful to identify the etiological agent (Fig. 1).

MEDIAN RESULTS OF CYTOKINES IN THE SKIN

MEDIAN RESULTS OF CYTOKINES IN THE SKIN

Table 1 Allergological investigation by lymphocyte activation text of PPI-related DHR

Table 1 Allergological investigation by lymphocyte activation text of PPI-related DHR

Table 1 Results

Table 1 Results

M male, F female, Pos positive, Neg negative, SPT skin prick tests, IDT intradermal test Table 1 Results

M male, F female, Pos positive, Neg negative, SPT skin prick tests, IDT intradermal test Table 1 Results

Table 1 Patients with angioedema (AE)+ urticaria tested with a HR-test

Table 1 Patients with angioedema (AE)+ urticaria tested with a HR-test

n=number of patients Table 1 (continued)

n=number of patients Table 1 (continued)

AD- | could be one of the determinants involved in CLV immediate allergic reactions. The inclusion of Clav2, a synthetic molecule derived from these determinants, can significantly improve the current BAT sensitivity using the parent drug. These findings may be important for the development of new in vitro tests for diagnosing CLV immediate allergic reactions.

AD- | could be one of the determinants involved in CLV immediate allergic reactions. The inclusion of Clav2, a synthetic molecule derived from these determinants, can significantly improve the current BAT sensitivity using the parent drug. These findings may be important for the development of new in vitro tests for diagnosing CLV immediate allergic reactions.

ND: not done Table 1 Characteristic of patient and test performed Methods

ND: not done Table 1 Characteristic of patient and test performed Methods

Table 1 Conclusion

Table 1 Conclusion

HSA-BP was produced at basic pH and analyzed by mass spectrometry MALDI-TOF analysis showing a covalent binding of an average of 15 molecules of BP per HSA molecule. In contrast to naive CD4+ T cells, HSA-BP was recognized by naive CD8+ T cells in only one donor out of five tested healthy donors. Since MHC class | molecules are classi- cally thought to present peptides derived from endogenous protein, we checked whether free BP can prime naive CD8+ T cells through direct intracellular protein haptenation in DCs. We were able to detect a naive CD8+ T cells repertoire for BP in the tested healthy donors. Moreover, the BP-specific CD8+ T cell response was MHC class | and proteasome-dependent (Fig. 1). Rami Bechara!, Marie-Eliane Azouri', Luc De Chaisemartin’, Sylvie Cho let-Martin!, Delphine Joseph?, Richard Weaver’, Bernard Maillére*, Mar Pallardy'

HSA-BP was produced at basic pH and analyzed by mass spectrometry MALDI-TOF analysis showing a covalent binding of an average of 15 molecules of BP per HSA molecule. In contrast to naive CD4+ T cells, HSA-BP was recognized by naive CD8+ T cells in only one donor out of five tested healthy donors. Since MHC class | molecules are classi- cally thought to present peptides derived from endogenous protein, we checked whether free BP can prime naive CD8+ T cells through direct intracellular protein haptenation in DCs. We were able to detect a naive CD8+ T cells repertoire for BP in the tested healthy donors. Moreover, the BP-specific CD8+ T cell response was MHC class | and proteasome-dependent (Fig. 1). Rami Bechara!, Marie-Eliane Azouri', Luc De Chaisemartin’, Sylvie Cho let-Martin!, Delphine Joseph?, Richard Weaver’, Bernard Maillére*, Mar Pallardy'

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (12)

  1. Clin Transl Allergy 2018, 8(Suppl 3):33
  2. Lumpur Royal College of Medicine Perak, Ipoh, Perak, Malaysia; 3 Immuno- genetic Unit, Allergy & Immunology Research Center, Institute for Medical Research, Kuala Lumpur, Malaysia; 4 Dermatology Department, Kuala Lum- pur Hospital, Kuala Lumpur, Malaysia Correspondence: Mohammed Faizal Bakhtiar -drfuzzy73@gmail.com Clinical and Translational Allergy 2018, 8(Suppl 3):P130 Clin Transl Allergy 2018, 8(Suppl 3):33
  3. Friday 20 april 2018 Clinical cases -Poster Walk 15 P140 Assessment of quality of life by means of specific questionnaire, in patients with suspected allergic drug reaction. Comparison before and after allergological study Gabriel Gastaminza 1 , Miguel Ruiz-Canela 2 , Mª José Barasona-Villarejo 3 , Rosario Cabañas 4 , Ignacio García-Núñez 5 , José Julio Laguna 6 , Teófio Lobera 7 , Marta López-San Martín 8 , Joaquín Martín-Lázaro 9 , Ruth Mielgo 10 , Esther Moreno 11 , M Carmen Moya 12 , Nancy R. Ortega-Rodríguez 13 , Patricia Rojas-Perez-Ezquerra 14 , Ana Rosado 15 , María Salas 16 , Leticia Sánchez-Moril- las 17 , Concepción Vila 18 , Mercè Corominas 19
  4. Clinica Universidad de Navarra, Pamplona, Spain; 2 Dpto. Medicina Preven- tiva y Salud Pública, Universidad de Navarra, Pamplona, Spain; 3 Hospital Universitario Reina Sofía, Córdoba, Spain; 4 Hospital La Paz Health Research Institute (IdiPAZ), Madrid, Spain; 5 Hospital Quironsalud Campo de Gibraltar, Cádiz, Spain; 6 Hospital Central Cruz Roja, Madrid, Spain; 7 Hospital de San Pedro, Logroño, Spain; 8 Hospital Universitario Puerta de Hierro-Majada- honda, Madrid, Spain; 9 Hospital Universitario Lucus Augusti, Lugo, Spain;
  5. Hospital Universitario 12 de Octubre, Madrid, Spain; 11 Complejo Asisten- cial Universitario de Salamanca, Salamanca, Spain; 12 Complejo Hospitalario Torrecárdenas, Almería, Spain; 13 Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain; 14 Hospital General Universitario Gregorio Marañon, Madrid, Spain; 15 Unidad de Alergia, Hospital Universi- tario Fundación Alcorcón, Madrid, Spain; 16 Hospital Regional Universitario de Málaga, Málaga, Spain; 17 Hospital Clínico San Carlos, Madrid, Spain;
  6. Hospital Universitario Severo Ochoa, Madrid, Spain; 19 Hospital Universi- tari de Bellvitge, L'hospitalet De Llobregat, Spain Correspondence: Gabriel Gastaminza -gastaminza@unav.es Clinical and Translational Allergy 2018, 8(Suppl 3):P140 Clin Transl Allergy 2018, 8(Suppl 3):33
  7. eyelid skin, through which chemicals more easily penetrate. In those cases, ROATs or provocative use tests are helpful. P153 Vemurafenib acts as an aryl hydrocarbon receptor antagonist Heike C. Hawerkamp 1 , Andreas Kislat 1 , Peter Arne Gerber 1 , Marius Pollet 2 , Anatoly A. Soshilov 3 , Michael S. Denison 3 , Afaque A. Momin 4 , Stefan T. Arold 4 , Angeliki Datsi 1 , Stephan A. Braun 1 , Mario E. Lacouture 5 , Thomas Haarmann-Stemmann 2 , Bernhard Homey 1 , Stephan Meller 1
  8. King Abdullah University of Science and Technology (KAUST), Computational Bioscience Research Center (CBRC), Division of Biological and Environmental Sciences and Engineering (BESE), Thuwal, Saudi Arabia; 5 Dermatology Service, Depart- ment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States Correspondence: Heike C. Hawerkamp -heike.hawerkamp@hhu.de Clinical and Translational Allergy 2018, 8(Suppl 3):P153
  9. INSERM UMR 996, Univ Paris-Sud, Université Paris-Saclay, 92290, Châtenay-Malabry, France; 2 UMR CNRS 8076, Univ Paris-Sud, Université Paris-Saclay, 92290, Châtenay-Malabry, France; 3 Institut de Recherches Internationales Servier, 92284, Suresnes, France; 4 SIMOPRO, IBiTecS, CEA, Saclay, France Correspondence: Rami Bechara -rami.bechara@u-psud.fr Clinical and Translational Allergy 2018, 8(Suppl 3):O06
  10. Clin Transl Allergy 2018, 8(Suppl 3):33
  11. Instituto Politecnico Nacional, Mexico City, Mexico; 2 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico;
  12. Cen- tro Medico Nacional La Raza, Mexico City, Mexico; 4 University of Liverpool, Liverpool, United Kingdom Correspondence: Alejandra Monroy -alemonroya@hotmail.com Clinical and Translational Allergy 2018, 8(Suppl 3):O09